Blood Test Predicts Melanoma Recurrence
TOPLINE: Droplet digital polymerase chain reaction (PCR) measurements of circulating tumor DNA (ctDNA) identify patients with stage III melanoma who are at high risk for early recurrence during adjuvant targeted therapy. The blood-based biomarker outperforms traditional prognostic indicators including tumor mutational burden and interferon gamma gene expression. METHODOLOGY: Cell-free ctDNA is an established measure of … Read more